600713 Nanjing Pharmaceutical
- 4.86
- +0.09+1.89%
Nanjing Pharmaceutical News
The pharmaceutical sector boosted and strengthened. Zhejiang Zhenyuan rose more than 5%, while Chinese Health, Heavy Pharmaceutical Holdings, Intel Group, Nanjing Pharmaceuticals, Sinopharm, and Kyushu Express followed suit.
The pharmaceutical sector boosted and strengthened. Zhejiang Zhenyuan rose more than 5%, while Chinese Health, Heavy Pharmaceutical Holdings, Intel Group, Nanjing Pharmaceuticals, Sinopharm, and Kyushu Express followed suit.
Nanjing Pharmaceutical (600713.SH) announced first-quarter results. Net profit of 1.59 yuan increased 6.65% year over year
Nanjing Pharmaceutical (600713.SH) released its report for the first quarter of 2024. The company achieved operating income of 1 during the reporting period...
NanJing Medical Plans to Issue Up to 6 Billion Yuan in Ultra Short-Term Bonds
NanJing Medical's (SHA:600713) plans to issue ultra-short-term bonds worth up to 6 billion yuan, according to a Monday filing with the Shanghai bourse. The bonds shall have an issuance period of up to
Express News | Six companies issued announcements related to share repurchases. Hisense Video has repurchased 351 million yuan of company shares
These 4 Measures Indicate That NanJing Pharmaceutical (SHSE:600713) Is Using Debt Extensively
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
Zhitong A Share Sale Restriction and Release List | February 2
According to the Zhitong Finance App, the ban on restricted shares of 8 listed companies was lifted on February 2, with a total market value of about 9.146 billion yuan. Today's specific sales restrictions and unbanned shares are as follows: Stock abbreviation, stock code, restricted stock type, number of banned shares, Xiamen, Xiangyu, 6000 57, share incentives, 5.3721 million, Nanjing Pharmaceutical, 600,713, share incentives, 5.2482 million, Supor 002032, share incentives, 555,800 Zijin Mining, 601,999 equity incentives, limited sales and circulation, 321.17 million, energy-saving wind power 60,117 million, energy-saving wind power, 601016 share incentives, limited sale and circulation of 8.033,500 Tianwei Food
Express News | The ban on restricted shares with a market capitalization of 8.955 billion yuan was lifted today. Huitai Medical lifted the ban and ranked first with a market value of 8.461 billion yuan
[BT Financial Report Momentary Analysis] Nanjing Pharmaceutical's 2023 Quarterly Report: Asset Growth and Cash Flow Challenges Under Steady Operation
As an important participant in the pharmaceutical distribution industry, Nanjing Pharmaceutical Co., Ltd. (stock code: 600713) directly serves the national medical and health industry. The company's business covers the procurement, warehousing, management and sale of pharmaceuticals and medical equipment, and is supervised by various national departments such as the Ministry of Commerce. Within the industry, Nanjing Pharmaceutical not only actively participated in the activities of industry self-regulatory organizations, but also continued to contribute to the development of the pharmaceutical distribution field. In terms of assets and liabilities, Nanjing Pharmaceutical's 2023 three-quarter report shows that the company's total assets increased from 31,651 billion yuan at the end of the previous year to 33.203 billion yuan, an increase
Nanjing Pharmaceutical (600713.SH): Application to issue convertible bonds accepted by the Shanghai Stock Exchange
Gelonghui, January 18, 丨 Nanjing Pharmaceutical (600713.SH) announced that on January 17, 2024, the company received the “Notice on Accepting the Application for Issuance of Securities by Nanjing Pharmaceutical Co., Ltd. Shanghai Main Board Listed Company” (Shanghai Stock Exchange) (Shanghai Stock Exchange) [2024] No. 20) issued by the Shanghai Stock Exchange (hereinafter referred to as the “Shanghai Stock Exchange”). The Shanghai Stock Exchange checked the prospectus and related application documents submitted by the company for the issuance of securities by a company listed on the Shanghai Main Board. It believed that the application documents were complete and complied with the legal form, and decided to accept them and review them in accordance with the law.
Nanjing Pharmaceutical (600713.SH): The company became one of the first companies to join the ESG branch of the China Pharmaceutical Business Association in 2023
On January 15, Ge Longhui Pharmaceutical (600713.SH) said on the investor interactive platform that ESG is a sustainable development concept and corporate evaluation standard that focuses on non-financial factors such as corporate environmental responsibility, social responsibility, and corporate governance. The company became one of the first companies to join the ESG branch of the China Pharmaceutical Business Association in 2023. It will continue to standardize governance, implement the social responsibilities of state-owned listed companies, implement the country's requirements for green development, adhere to green and low-carbon development, and do a good job of energy saving and emission reduction.
NanJing Pharmaceutical's (SHSE:600713) Five-year Earnings Growth Trails the Notable Shareholder Returns
When you buy and hold a stock for the long term, you definitely want it to provide a positive return. Furthermore, you'd generally like to see the share price rise faster than the market. Unfortunat
Pharmaceutical commercial stocks rose, Zhejiang Zhenyuan, and Nanjing pharmaceutical rose and stopped
Gelonghui, December 13 | Zhejiang Zhenyuan and Nanjing Pharmaceutical both rose and stopped, while Intel Group, E-Buy Pharmaceutical, Celi Healthcare, and Kaikai Industrial followed suit.
Nanjing Pharmaceutical (600713.SH): The fund participating in the investment establishment has now invested in a high-end medical consumables R&D and industrialization enterprise
Gelonghui November 17丨Nanjing Pharmaceutical (600713.SH) said at the performance briefing that the company participated in the establishment of the Nanjing New Industrial Healthcare Industry Investment Partnership (Limited Partnership), which the company participated in the investment and establishment of, will rely on the XinGong Investment Group and the company's industry and carrier resources, and focus on “specialized and new” enterprises in the field of new medicine and life and health, and explore a number of technology-based, technological research and development, and product-driven enterprises in the medical and health sector, which will help the company expand the breadth of the industry through investment, strengthen the company's industrial transformation and upgrading, and strengthen market competitiveness. The fund has now invested in a high-end medical consumables research company
Nanjing Pharmaceutical (600713.SH) released the first three quarter results, net profit of 440 million yuan, a year-on-year decrease of 6.37%
Nanjing Pharmaceutical (600713.SH) released a report for the first three quarters of 2023, with revenue of 40.547 billion yuan...
What NanJing Pharmaceutical Company Limited's (SHSE:600713) ROE Can Tell Us
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for those who would like to learn about Return On Equity (ROE). To keep the less
[Instant Analysis of BT Financial Report] Nanjing Pharmaceutical's 2023 Interim Report: Operating income increased by 14.21%, net profit declined slightly, and balance ratio rose slightly
Nanjing Pharmaceutical Co., Ltd. (stock code: 600713) is a company operating in the pharmaceutical distribution industry. It is mainly responsible for the procurement, storage, management and sales of pharmaceuticals. According to its 2023 semi-annual report, we can see how the company has been doing for the past six months. First, judging from the balance and liabilities situation, the total balance of assets at the end of the period of Nanjing Pharmaceutical was 334 billion yuan, an increase compared to 317 billion yuan at the beginning of the period. The total closing balance of liabilities was 264 billion yuan, up from 250 million yuan at the beginning of the period. This shows that the company is well-placed in terms of assets and liabilities
Nanjing Pharmaceutical (600713.SH): The target revenue in 2023 will be higher than the average growth rate of the industry, and the increase is expected to be higher than 10%
Gelonghui, September 13丨Nanjing Pharmaceutical (600713.SH) said at the semi-annual performance briefing that the company's 2023 budget target: operating income and total profit after deducting non-recurring profit and loss will continue to achieve double growth. Among them, revenue will target a higher growth rate than the industry average, with an increase of more than 10%.
Nanjing Pharmaceutical (600713.SH): The network layout has been completed in the Yichang region of Hubei this year, and is underway in other regions
At the semi-annual performance briefing, Nanjing Pharmaceutical (600713.SH) said at the semi-annual performance briefing that the company is based on the development position of a regional group enterprise, endogenous growth combined with epitaxial expansion, strives to deeply cultivate existing key business regions, continue to improve and deepen the terminal market network and professional segment layout, horizontal expansion and vertical sinking, and strengthen the decline of grass-roots terminals under the guidance of the new “strong grassroots” policy. Relying on geographical advantages and scale effects, the company continuously enhances regional market coverage and influence. The company has completed the network layout in Yichang, Hubei this year, and is in progress in other regions.
Nanjing Pharmaceutical (600713.SH): According to the company's 14th Five-Year Development Plan, the company's balance ratio target is controlled within 75%
Gelonghui, September 13丨Nanjing Pharmaceutical (600713.SH) said at the semi-annual performance briefing that the company meets the development needs of the main business through multi-channel financing and continuously reduces financing costs. Currently, the comprehensive financing cost is about 3.1%. According to the company's 14th Five-Year Plan, the company's balance ratio target is kept within 75%. By issuing medium- to long-term financing instruments such as medium-term notes and convertible bonds, the company increases medium- to long-term financing and reduces the short-term debt ratio.
Nanjing Pharmaceutical (600713.SH): Plans to jointly invest 200 million yuan to establish an investment partnership in Nanjing's new medical and health care industry
Gelonghui, September 4, 丨 Nanjing Pharmaceutical (600713.SH) announced that on September 1, 2023, the company officially signed the “Nanjing New Engineering Healthcare Industry Investment Partnership (Limited Partnership)” with Xinkong Industrial Investment, New Engineering Investment Group, Jiangning High-tech Venture Capital, Jiangning Industrial Development Fund, and Jiangning Tianyin No.1 Fund, and jointly invested 200 million yuan to establish the Nanjing Xingong Healthcare Industry Investment Partnership (Limited Partnership). One new limited partner was added to Jiangning Tianyin No.1 Fund, which invested 20 million yuan, accounting for 10% of the total amount pledged by the fund. The investment of the Jiangning Industrial Development Fund was adjusted to
Analysis
Price Target
No Data
